<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79040">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076503</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1513</org_study_id>
    <nct_id>NCT02076503</nct_id>
  </id_info>
  <brief_title>Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status</brief_title>
  <official_title>Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment,
      accurate staging of the disease at the time point of diagnosis is important. The objective
      of this study is to evaluate the diagnostic potential of a combined PET/MR examination for
      risk assessment and detection of lymph node metastases. The overall aim of the project is to
      improve the investigators ability to provide individually tailored treatment to prostate
      cancer patients.

      The study will include 32 men with high-risk prostate cancer, who are eligible for radical
      prostatectomy. Informed consent is a requirement for inclusion in the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and negative predictive value of 18FACBC PET/MR for detection of lymph node metastases</measure>
    <time_frame>7 days</time_frame>
    <description>Findings on 18FACBC PET/MR images will be compared to histopathology, which is considered the gold standard for evaluation of pelvic lymph node metastases</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET-MR 18f-FACBC</intervention_name>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>histology (gold standard)</intervention_name>
    <description>histopathological classification of co-located dissected lymph nodes</description>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High-risk prostate cancer according to EAU guidelines (Gleason score ≥8 and/or PSA
             ≥20 ng/ml and/or ≥ cT3a cancer)

          -  Eligibility for the surgical procedure (radical prostatectomy and bilateral pelvic
             lymph node resection)

        Exclusion Criteria:

          -  Previous treatment (for example TURP or hormone therapy)

          -  Contraindication for the PET/MR examination (including, but not limited to:
             pacemaker, aneurysm clips, reduced renal function, metal implants, claustrophobia)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Angelsen, prof</last_name>
    <role>Study Director</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Urologic Surgery, St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 13, 2016</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm Staging</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>1-amino-3-fluorocyclobutane-1-carboxylic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
